These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34220861)

  • 1. Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2.
    Fernández-Lázaro D; Fernandez-Lazaro CI; Mielgo-Ayuso J; Adams DP; García Hernández JL; González-Bernal J; González-Gross M
    Front Immunol; 2021; 12():698672. PubMed ID: 34220861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3.
    Villarrubia VG; Moreno Koch MC; Calvo C; González S; Alvarez-Mon M
    Immunopharmacol Immunotoxicol; 1997 Feb; 19(1):53-74. PubMed ID: 9049659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergence between global BCG vaccination and COVID-19 pandemic.
    Islam MZ; Zahan MK; Al-Bari MAA
    J Med Virol; 2021 Mar; 93(3):1496-1505. PubMed ID: 32827313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
    Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
    Front Immunol; 2021; 12():729189. PubMed ID: 34603303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19.
    Lai YJ; Chang HS; Yang YP; Lin TW; Lai WY; Lin YY; Chang CC
    J Chin Med Assoc; 2021 Sep; 84(9):821-826. PubMed ID: 34282078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
    Kumar S; Çalışkan DM; Janowski J; Faist A; Conrad BCG; Lange J; Ludwig S; Brunotte L
    Front Immunol; 2021; 12():752227. PubMed ID: 34659259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis.
    Woopen C; Schleußner K; Akgün K; Ziemssen T
    Front Immunol; 2021; 12():701752. PubMed ID: 34234787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
    Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
    Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on COVID-19: SARS-CoV-2 life cycle, immunopathology, and BCG vaccination.
    Khade SM; Yabaji SM; Srivastava J
    Prep Biochem Biotechnol; 2021; 51(7):650-658. PubMed ID: 33226885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
    Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
    Front Immunol; 2021; 12():803647. PubMed ID: 35095889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AM3, a natural glycoconjugate, induces the functional maturation of human dendritic cells.
    Martín-Vilchez S; Molina-Jiménez F; Alonso-Lebrero JL; Sanz-Cameno P; Rodríguez-Muñoz Y; Benedicto I; Roda-Navarro P; Trapero M; Aragoneses-Fenoll L; González S; Pivel JP; Corbí AL; López-Cabrera M; Moreno-Otero R; Majano PL
    Br J Pharmacol; 2008 Jun; 154(3):698-708. PubMed ID: 18414382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AM3 inhibits HBV replication through activation of peripheral blood mononuclear cells.
    Majano P; Roda-Navarro P; Alonso-Lebrero JL; Brieva A; Casal C; Pivel JP; López-Cabrera M; Moreno-Otero R
    Int Immunopharmacol; 2004 Jul; 4(7):921-7. PubMed ID: 15182731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine.
    Zhao D; Chen X; Wang L; Zhang J; Zhao Z; Yue N; Zhu Y; Fei W; Li X; Tan L; He W
    Int J Biol Macromol; 2023 Apr; 234():123635. PubMed ID: 36801224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell immunity to SARS-CoV-2 following natural infection and vaccination.
    DiPiazza AT; Graham BS; Ruckwardt TJ
    Biochem Biophys Res Commun; 2021 Jan; 538():211-217. PubMed ID: 33190827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis.
    Albillos A; Nieto M; Ubeda M; Muñoz L; Fraile B; Reyes E; Lledó L; Blanco I; Pastor O; Salas C; Lario M; Monserrat J; Bataller R; Alvarez-Mon M
    Gut; 2010 Jul; 59(7):943-52. PubMed ID: 20442198
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.